Table 1.
Baseline characteristics of the population at the time of crizotinib initiation (n = 106)
| Characteristics, n (%) | All patients | PRR group | LTR group | P | |
|---|---|---|---|---|---|
| Age, years | 50 ± 10.7 | 52 ± 9.7 | 49 ± 10.9 | ||
| < 60 | 83 (78.3) | 20 (71.4) | 63 (80.8) | 0.304 | |
| ≥ 60 | 23 (21.7) | 8 (28.6) | 15 (19.2) | ||
| Gender | |||||
| Male | 56 (52.8) | 17 (60.7) | 39 (50.0) | 0.330 | |
| Female | 50 (47.2) | 11 (39.3) | 39 (50.0) | ||
| Smoking status | |||||
| Never smoker | 72 (67.9) | 17 (60.7) | 55 (70.5) | 0.341 | |
| Former smoker | 34 (32.1) | 11 (39.3) | 23 (29.5) | ||
| Histology | |||||
| Adenocarcinoma | 100 (94.3) | 25 (89.3) | 75 (96.2) | 0.383 | |
| Other† | 6 (5.7) | 3 (10.7) | 3 (3.8) | ||
| ECOG PS | |||||
| 0–1 | 96 (90.6) | 20 (71.4) | 76 (97.4) | < 0.001 | |
| 2–3 | 10 (9.4) | 8 (28.6) | 2 (2.6) | ||
| Line of therapy before crizotinib | |||||
| 0 | 64 (60.4) | 13 (46.4) | 51 (65.4) | 0.079 | |
| ≥ 1 | 42 (39.6) | 15 (53.6) | 27 (34.6) | ||
| Metastasis site | |||||
| Brain | 25 (23.6) | 8 (28.6) | 17 (21.8) | 0.469 | |
| Lung | 47 (44.3) | 11 (39.3) | 36 (46.2) | 0.530 | |
| Pleural | 42 (39.6) | 10 (35.7) | 32 (41.0) | 0.622 | |
| Liver | 11 (10.4) | 6 (21.4) | 5 (6.4) | 0.061 | |
| Bone | 28 (26.4) | 10 (35.7) | 18 (23.1) | 0.193 | |
| Lymph node | 64 (60.4) | 19 (67.9) | 45 (57.7) | 0.346 | |
| Others‡ | 8 (7.5) | 1 (3.6) | 7 (9.0) | 0.609 |
†
Includes squamous, adenosquamous, and large cell carcinomas.
‡
Includes adrenal and subcutaneous metastases. BM, brain metastasis; ECOG PS, Eastern Cooperative Oncology Group performance status; LTR, long‐term responder; NSCLC, non‐small cell lung cancer; PRR, primary‐resistant responder.